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Abstract 
The caudate putamen is a sub region of the basal ganglia, containing neural tracts important for 
cognition, reward learning, and voluntary motor function. Dopamine (DA) signaling received 
from the dopaminergic neurons of the substantia nigra pars compacta mediate locomotion, 
degradation of which is the characteristic neuropathology for Parkinson’s disease (PD). PD is an 
initially neurovegetative motor disorder but can progress to include cognitive impairments as 
well. Sundowner’s syndrome (SS) has been observed in patient populations with 
neurodegenerative diseases, characterized by the decline of cognition into evening hours. Due 
to the circadian influence which the hormone melatonin has on the sleep-wake cycle, attention 
has been drawn to its relationship with SS. While melatonin has been observed to decrease DA 
release, the real-time measurement of acute melatonin exposure on DA release within the 
caudate has yet to be studied. Utilizing various techniques of fast scan cyclic voltammetry (FSCV) 
in an ex vivo mouse model, we observed a decrease in DA release upon exposure to 
supraphysiological concentrations of melatonin. Results from this experiment support previous 
literature suggesting that activation of presynaptically expressed melatonin receptor 1 (MT1) 
plays an important physiological role in downregulating DA release. Additionally, results suggest 
that 1-hour of MT1 activation is a sufficient time-frame for significant downregulation of DA 
availability. This research seeks to deepen understanding of the complex roles melatonin has on 
neurotransmission.  
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Chapter 1 
Early Zebrafish Trials 
The Technique 
Fast scan cyclic voltammetry (FSCV) has the ability to record the release of 
neurotransmitters from neurons in real time. FSCV works on the principle that some 
compounds, like dopamine (DA), are electroactive and capable of losing or gaining 
electrons given the right electrochemical conditions. By delivering a constant or cyclic 
voltage potential via a carbon fiber micro-electrode (CFme) inserted into nervous tissue 
we can create conditions to influence DA when to lose or gain its electrons while also 
simultaneously reading the movements they make. By measuring the magnitude of 
alternating current produced by these electron movements, we can quantify the 
concentration change of DA over time (Wassum & Phillips, 2015; Zachek, Hermans, 
Wightman, & McCarty, 2008).  
 DA belongs to a class of organic compounds called the catecholamines. 
containing a benzene ring with one side chain amine and two hydroxyl groups at the 
first and second carbon. As outlined in Figure 1, one electron is taken from each 
hydroxyl group when the oxidation potential is reached by the CFme, converting 
dopamine to dopamine-o-quinone and back into DA via oxidation-reduction reactions. 
Utilizing Demon Voltammetry Software (Wake Forest Innovations), the CFme is typically 
programmed to increase and decrease in voltage (V) in a linear and repeated fashion 
from the holding potential of -0.4V to the switching potential of +1.3V. DA experiences 
oxidation and reduction at voltage potentials of +0.6V and -0.2V, respectively compared 
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to a silver/silver chloride reference electrode. Utilizing software, the background current 
can be subtracted from what is read at the CFme, highlighting the difference in current 
across voltages and time allowing for the visualization of data as a background-
subtracted color plot as shown in Figure 2. Historically, FSCV has proven itself to be a 
powerful electrochemical technique for measuring neurotransmitter release and 
reuptake in real time due to the sub-second temporal resolution of data collection. 
 DA is well documented as being a critical component in both physiological and 
cognitive processes (Marsden, 2006). FSCV is often used to deepen understanding of 
neurophysiological changes caused by environmental factors. Examples of this include 
observing the acute effects of certain psychoactive drugs on the release and uptake of 
neurotransmitters that play pivotal roles in the central nervous system (Ramsson, 
Howard, Covey, & Garris, 2011). However, FSCV can be used to observe the effects of 
learning as well. Demonstrated by previous studies, recording DA release can provide 
insight of what behavioral changes look like at the neurophysiological level.  
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Figure 1. Basic FSCV principles: A cyclic voltage waveform is applied to the CFme (A), 
causing dopamine to lose and gain electrons (B). The current generated from these 
electron movements is then recorded and subtracted from the background current to 
produce a cyclic voltammogram (C). 
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Figure 2. Background-subtracted color plot of stimulated DA release: A) 2D color plot 
of electrically evoked DA release. B) 3D representation of color plot in figure A. C) 
Current versus time graph at DA’s oxidation potential, representative of the blue line 
which transects the color plots of figures A and B. D) Background-subtracted 
voltammogram just after tissue stimulation, representative of the red line which 
transects the color plots of figures A and B. Note DA’s characteristic oxidation and 
reduction peaks. Time of stimulation occurs at 5 seconds, illustrated as the green 
dashed line in figure C. 
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Properties of Dopamine as a Neuromodulator 
 DA is one of several neurotransmitters that have secondary roles as 
neuromodulators, capable of effecting synaptic strength and membrane protein 
expression of individual neurons (Marder & Thirumalai, 2002). This modulatory property 
of DA and associated membrane proteins is essential to why it has been observed to 
have roles involved with the process of learning and memory. Synaptic strength can be 
upregulated or downregulated by many pre- and post-synaptic mechanisms resulting in 
physiological changes such as the amount of neurotransmitter released or rate of 
uptake (Owen & Brenner, 2012; Tellez, Gómez-Víquez, & Meneses, 2012). Measurement 
of DA release profiles utilizing FSCV allows for the indication that neuromodulation has 
occurred.  
Flagel et al. (2011) explored reward learning in rats by observing phasic DA 
release in the mesolimbic system during operant conditioning. Upon receiving what the 
body deems as a desired stimulus such as food in this case (unconditioned stimulus, US), 
DA is released as a reward. Presenting rats with a push-lever (conditioned stimulus, CS) 
which provided the rat with food upon activation will lead to a shift in DA release from 
the US to the CS upon repetition. This reward learning process is fundamental for the 
reinforcement of actions and an organism’s prediction of positive stimuli. FSCV was used 
to observe DA release in the nucleus accumbens core of rats during a Pavlovian training 
routine as described above. Repeated training sessions observed peak DA release to 
gradually shift from the US to the CS (Doya, 2002; Flagel et al., 2011; Ilango, Shumake, 
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Wetzel, Scheich, & Ohl, 2012). This experiment demonstrates the modulation of DA 
release in response to factors presented by the environment. 
While studies such as Flagel et al. (2011) sought to observe changing DA profiles 
over a conditioning period, we hypothesized that we could compare the DA profiles of a 
conditioned animal versus an unconditioned animal. Through a training paradigm, we 
questioned if it was possible to promote learning to an extent that which the 
measurable DA release profile becomes significantly different than a control. With that 
research goal in mind we promptly began to seek out possible model organisms. 
The Proposed Experiment 
 The methods for experimentation were inspired by a publication from a research 
group which was one of the first to explore the use of FSCV in Danio rerio, more 
commonly known as zebrafish (Jones, McCutcheon, Young, & Norton, 2015). Zebrafish 
are an appealing model organism since they possess a high degree of neurophysiological 
similarity to their mammalian counterparts. In addition to the physiological aspects, 
over 70% of human genes have an orthologue in zebrafish which together provide a 
foundation for effective human neurobehavioral disorder and disease modeling (Howe 
et al., 2013). Moreover, the lower costs of housing, feeding, and maintenance compared 
to popular mammalian model organisms was ideal. 
Zebrafish are prominent model organisms used for studying learning and 
memory by displaying a capacity to learn avoidance and spatial paradigms under lab 
conditions (Naderi, Jamwal, Chivers, & Niyogi, 2016). Some conditioning studies may 
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administer a mild electric shock to the zebrafish as an US. Mitogen Activated Protein-
mapping has indicated that the region of the brain which undergoes the most activity 
while being exposed to shock stimuli is the telencephalon (Randlett et al., 2015). 
Additionally, the dorsolateral and dorsomedial subsections of the telencephalon have 
been suggested to be the regions of the brain responsible for spatial learning and 
avoidance learning, respectively (Xu et al., 2012). Studies which have conducted 
anatomical imaging such as confocal microscopy and immunolabeling techniques have 
helped elucidate specific dopaminergic pathway locations within the zebrafish 
telencephalon which are suspected to be involved with avoidance learning and memory 
(Kaslin & Panula, 2001; Tay, Ronneberger, Ryu, Nitschke, & Driever, 2011). 
We proposed that through experimentation we could measure evoked DA 
release in the dorsomedial telencephalon of control zebrafish utilizing FSCV. Then, after 
being subjected to an avoidance paradigm, test-group zebrafish would also have the 
same brain region analyzed. We hypothesized that the fish which were put through 
avoidance training would have a significantly greater DA profile than their control 
counterparts. However, simply the task to collect control data became an extended 
exercise in creativity and patience. 
Data collection 
We had hoped that the process of collecting voltammetry data would be straight 
forward. The framework for our methods of ex vivo data collection was initially very 
similar to Jones et al. (2015) as they appeared to be reasonably repeatable. Primarily 
  
 
14 
 
using Kaslin & Panula (2001) as an atlas for dopaminergic regions, many attempts were 
made to match location and depth of these regions. However, even placing the CFme in 
DA rich areas like the olfactory bulbs yielded no viable data.  
Iontophoresis in tissue 
Without any clear indication of DA release, the question arose if we were simply 
not administering a strong enough electrical pulse to elicit DA release or if our 
equipment was not sensitive enough to detect release events. Considering alternative 
methods brought us to the possibility of introducing DA into the system and then 
measuring the reuptake as a means to quantify change in synaptic strength. This is the 
fundamental basis of iontophoresis, i.e. discrete and controlled injection of drugs into 
tissue alongside a CFme for FSCV recording. 
 Electroactive compounds are dissolved in solution and injected into a capillary 
which has been pulled to create a type of pipette needle. A wire is inserted into the 
exposed and wider end allowing for the application of an electric current. The applied 
current by the wire will cause electrical migration of compounds out of the capillary and 
into the target environment (Herr, Daniel, Belle, Carelli, & Wightman, 2010). While 
preliminary buffer work showed some promising results, most attempts were 
inconsistent with DA having the tendency to leak out of the capillary uncontrollably. We 
concluded that the diameter of our manufactured pipettes was simply too wide for 
proper iontophoresis work. Without the means for more precise pipette manufacturing 
we sought alternative options. 
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Olfactory Stimulation 
Upon referring to the literature we found a paper demonstrating use of olfactory 
stimulation to elicit DA release through the zebrafish’s own neuronal circuitry. As 
mentioned previously, the olfactory bulb of the zebrafish is a region which is highly 
dopaminergic. Zebrafish receive olfactory input from a pair of nasal florets, akin to the 
olfactory epithelium in humans. By grinding fish food into a fine powder and mixing it 
into water we could create a solution which could be pipetted onto the fish’s florets and 
cause an excitatory response within the olfactory bulb of the fish (Shang et al., 2015). 
We adjusted our methods slightly so that we could accurately pipette food 
particles. The zebrafish was pinned in place within a 3D printed chamber which could be 
filled with artificial cerebral spinal fluid (aCSF) to nourish brain tissue through a reflected 
scalp. With the electrode inserted into the olfactory bulb we would begin recording and 
pipette food particles to the florets. Unfortunately, while the electrode did sometimes 
experience activity, we determined later that it was likely caused by pH changes in the 
environment, fish food reacting with the electrode, or the physical forces applied to the 
fish from food particle pipetting. Once again, we found ourselves without a viable 
option for collecting control data. 
Inverted Microscopy  
 To eliminate possible cause of error, we began to reason that perhaps we simply 
did not possess the precision to accurately place the electrode. Through the university, 
our lab came to acquire an inverted microscope (Zeiss Microscopy) from another 
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department. With this inverted microscope we now had the ability to place a CFme with 
the spatial precision of single micrometers. In addition to our new equipment, we 
decided to explore evoking DA release through chemical stimulation as opposed to 
electrical. Flooding a tissue slice with aCSF containing a high concentration of potassium 
chloride (KCl) will create a strong ion imbalance across neuronal membranes which will 
in turn cause exocytotic release of neurotransmitters from axon terminals. This method 
has been used widely in the literature to elicit strong and continuous release of 
neurotransmitters (Heaulme, Leyris, Le Fur, & Soubrie, 1997).  
Unfortunately, KCl proved difficult to work with and did not provide data of 
acceptable quality. Among other issues, introduction of a separate aCSF to our tissue 
flow chamber produced a pH change which affected our background signal and data 
recording. Additionally, we discovered the inverted microscope itself introduced 
electrical noise into our data recordings which made the interpretation of results 
difficult. Though we did produce a single data set which vaguely displays the redox 
profile of DA, the lack of repeatability questions its legitimacy as valid data. Eventually 
we decided that this too was unlikely to produce fruitful results. 
Conclusions 
 Though much time was invested in searching for DA release throughout the 
zebrafish brain, all methods we tried were not viable. Whether it be issues with 
repeatability, manufacturing of materials, or simply lack of data, we concluded that we 
had truly exhausted our options. While it was difficult to accept defeat, the foundational 
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skills in voltammetry I had acquired allowed me to tackle the new techniques that were 
to come. I soon came to discover the excitement of scientific research in the project that 
followed and eventually became the main subject of this thesis.  
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Chapter 2 
Introduction to Mouse Slice Work 
Background 
The catecholaminergic neurotransmitter DA has been well-documented to have 
important roles within the central nervous system. The basal ganglia of vertebrate 
species, including humans, is a group of subcortical nuclei within the forebrain 
containing neural tracts involved with voluntary motor function, cognition, and reward-
learning pathways associated with habit formation. Classified as a subregion of the 
dorsal striatum within the basal ganglia, the caudate putamen receives signaling 
responsible for coordinating locomotion (Budygin et al., 2007; Hashemi et al., 2012). 
Studying DA insufficiencies within the striatum has become a particularly important 
topic among medical researchers due to its association with serious disorders such as 
Parkinson’s disease (PD), primarily characterized by neuronal loss in the substantia nigra 
with dopaminergic denervation of the dorsolateral striatum (Dagher & Robbins, 2009; 
Mack et al., 2016). In the early stages of PD, the disease manifests itself as a motor 
disorder often causing bradykinesia, tremors, rigidity, and postural instability. However, 
later stages of PD sees patients experience cognitive dysfunction as well with up to 80% 
developing Parkinson’s disease dementia (PDD),  (Gratwicke, Jahanshahi, & Foltynie, 
2015; Irwin et al., 2012; Mack et al., 2016). The physiological mechanisms of the non-
motor symptoms of PD remain poorly understood (Mack et al., 2016). 
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A phenomenon which has been widely observed in the elderly with 
neurodegenerative disorders is the acute worsening of symptoms in the late evening 
and into the night. Increased confusion, hallucinations, agitation, aggression, anxiety, 
repetitive or disruptive vocalization, restlessness, and pacing or wandering have become 
characteristic of what is known as sundown syndrome (SS) (Cipriani, Lucetti, Carlesi, 
Danti, & Nuti, 2015; Hazelton, 2006; Silva, Sousa-Muñoz, Frade, Fernandes, & 
Magalhães, 2017). While neuropsychiatric symptoms for the syndrome have been well-
documented, it lacks a clear definition and remains a descriptive term rather than a 
diagnosis (Canevelli et al., 2016; Silva et al., 2017). Although the precise neuropathology 
is still widely debated, much attention is drawn to the circadian nature which has been 
observed with SS.  
Circadian rhythms are physiological cycles which occur in mammals roughly over 
a 24-hour period governed by the suprachiasmatic nucleus (SCN) of the brainstem. One 
of several biological processes under circadian control is the release of hormones in 
response to environmental lighting conditions to influence the sleep-wake cycle (Stone 
& Tranah, 2017). Via the retinohypothalamic tract, intrinsically photosensitive retinal 
ganglion cells within the retina convey light information directly to the SCN of the 
hypothalamus. From the SCN, projections carry circadian signaling to numerous brain 
regions, some of which mediate signaling further to endocrine tissues such as the pineal 
gland (Moore, 1995). While it has been discovered to be synthesized in small amounts 
among several tissues, the hormone melatonin is released most prominently by the 
pineal gland as part of the sleep-wake circadian rhythm. Its release is influenced by 
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environmental lighting conditions, with release generally being suppressed during the 
day and peak release being seen in the middle of the night (Kozaki, Kubokawa, 
Taketomi, & Hatae, 2015; Valdés‐Tovar et al., 2018). The release of melatonin is most 
widely known to promote sleep, but studies in recent decades have begun to uncover 
the breadth of interaction melatonin has on various brain regions. 
Melatonin Effects on Neurotransmission 
 The two major subclasses governing the receptor mediated communication 
between neurons upon DA release are the D1-like and D2-like (D1R and D2R) receptor 
families. The distinction is based on their downstream physiological effects upon 
activation. Both D1R and D2R belong to the family of seven transmembrane domain G-
protein coupled receptors (GPCR) whose signal transduction pathways generally work in 
opposition of each other. D1R is exclusively expressed post-synapse, with ligand binding 
resulting in activation of adenylyl cyclase (AC). AC acts to convert adenosine tri-
phosphate (ATP) into cyclic adenosine mono-phosphate (cAMP). High levels of cAMP 
allow for the activation of protein kinase A (PKA) which will go on to phosphorylate 
numerous proteins involved with metabolism, transcription, and ion channel function 
often directly relating to transduction of action potentials. The effects of D1R are 
viewed as excitatory in nature, as opposed to the effects of D2R activation (Vallone, 
Picetti, & Borrelli, 2000).  
 Though D2R has been observed to have heterogeneous post-synaptic expression 
in the striatum, we will be primarily discussing its more common role as a presynaptic 
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autoreceptor to focus on regulatory aspects of DA release. Acute activation of D2R 
primarily causes feedback inhibition of exocytotic release of DA from axon terminals. 
This response is mediated through G-protein βɣ-subunits which inhibit functionality of 
voltage-gated calcium channels (VGCC). Depreciation of calcium influx to the axon 
terminal inhibits the fusion of DA containing synaptic vesicles to the plasma membrane 
residing within the synaptic cleft. In other words, successive activation of D2R will 
reduce likelihood of continuous DA release from action potentials for a period lasting up 
to several seconds. Sustained activation of D2R will result in downregulation of AC, 
inhibiting intracellular cAMP levels and decreasing the abundance of PKA. The 
downstream effects of this include inactivation of tyrosine hydroxylase (TH), a rate 
limiting enzyme pivotal to the formation of DA precursor L-DOPA. Inhibition of DA 
synthesis will subsequently decrease DA availability for neurotransmission (De Mei, 
Ramos, Iitaka, & Borrelli, 2009; Ford, 2014; Vallone et al., 2000; Yapo et al., 2017).  
 Inhibitory effects of melatonin on mammalian dopaminergic release have been 
observed since the 1980’s. Though the structure and function of melatonin receptors 
have been studied for decades, research uncovering melatonin’s role in 
neurotransmission is more recent. Melatonin has been known to exert its physiological 
effects on the body through melatonin receptors 1 and 2 (MT1 and MT2). Like DA 
receptors, MT1 and MT2 belong to the extensive family of seven transmembrane 
GPCRs. Similar to D2R activation, the most well-defined signaling pathway for MT1 is the 
inhibition of intracellular cAMP accumulation via inactivation of AC (Dubocovich et al., 
2010). These similarities suggest MT1 could produce similar downregulatory effects as 
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D2R depending on localized expression. Chronic activation of the MT1 receptor by 
circadian melatonin levels could possibly contribute to the known diurnal variation of 
DA availability (Ferris et al., 2014). 
Past immunolabeling and cellular expression studies have established that the 
dopaminergic systems within the caudate putamen of both human and rodents express 
the melatonin receptor MT1. Moreover, MT1 and D2R are colocalized on the 
presynaptic Dopaminergic axon terminals which communicate within the caudate 
putamen (Uz et al., 2005). A recent study by Benleulmi-Chaachoua et al. (2015) sought 
to explain the mechanisms of action  MT1 uses to attenuate VGCC activity which has 
been previously observed in the literature (Zisapel, 2001). It was confirmed that 
activation of striatal pre-synaptic MT1 receptors physically interact with VGCC of axon 
terminals to downregulate activity. As described above, inhibition of calcium influx will 
result in decreased DA release. Other striatal melatonin-mediated changes that have 
been reported include increased D2 receptor affinity (Hamdi, 1998). Function of the 
D1R, D2R, and MT1 receptors have been illustrated in Figure 3. 
With this basis of knowledge, we should expect to see decreased stimulated DA 
release in the striatum of a mouse model upon melatonin exposure. However, real-time 
data on the time dependent effects which melatonin has on striatal DA release is yet to 
be observed. We propose the employment of FSCV as a tool to provide insight on the 
progressive decrease in DA release upon prolonged exposure to melatonin.  
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Figure 3. Receptor role in striatal DA release: The red arrows and green arrows 
represent a downregulatory and upregulatory response, respectively. (1) Acute 
activation of the D2R autoreceptor and MT1 receptor will result in inhibited function of 
the voltage gated calcium channel (VGCC). (2) Chronic activation of the D2R auto 
receptor and MT1 receptor will result in inhibited function of adenylyl cyclase (AC), 
decreasing cAMP accumulation and downregulating downstream enzymes important to 
DA synthesis. (3) D1R activation will upregulate AC, increasing cAMP accumulation 
allowing for an excitatory response altering cellular metabolism and ion channel 
function. 
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FSCV 
As previously described in chapter 1, background-subtracted FSCV has shown to 
be an effective electrochemical technique for measuring neurotransmitter release and 
reuptake. Application of this technique is well-suited to the task at hand due to the high 
temporal resolution of real-time sub-second data collection (Hermans, Keithley, Kita, 
Sombers, & Wightman, 2008). Current is recorded in the order of nano-amps (nA); the 
amplitude of which correlates with the change in concentration of reactive analytes. 
Due to the diversity of oxidation potentials among organic compounds, the cyclic 
voltammogram for each electroactive neurochemical is unique. DA, for example, has 
become one of the most well-defined analytes in the field with known oxidation and 
reduction potentials being -0.2V and +0.6V, respectively. 
FSCV can be utilized to detect DA concentrations upon electrically evoked axonal 
release within ex vivo tissue slices. Work with ex vivo tissue slices allow for simplified 
access to brain regions of interest and faster diffusion of drugs into tissue. However, 
there are some factors to consider when utilizing voltammetry. Complications in 
collection technique can arise when the drug of choice is also an electroactive 
compound. 
Challenges of ex vivo FSCV 
Melatonin is classified as an indolamine, a subclass of the monoamine 
neurotransmitters which include DA. Due to similar functional groups, melatonin is 
electroactive and capable of adsorbing to the CFme. It has been observed to cause 
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impedance, or fouling, of the CFme surface which results in decreased sensitivity to 
analytes (Hensley, Colley, & Ross, 2018). In order to reduce the confounding effects of 
fouling, three different voltammetry techniques will be employed. Consistency among 
the collection techniques will support the argument that what we observe is a biological 
effect and not misrepresented due to fouling. 
The first method to be utilized will be a waveform used in fast-scan controlled-
adsorption voltammetry (FSCAV). Developed by Atcherley et al. (2013), it is a technique 
originally designed to minimize DA adsorption to the CFme surface by increasing both 
the scan rate and frequency of the voltage waveform. We believe that by decreasing 
adsorption of DA we will also decrease adsorption of other analytes which would 
otherwise cause impedance of the CFme surface, like melatonin. One drawback to be 
expected from this waveform will be a decreased sensitivity to DA due to the decreased 
time available for adsorption between scans.  
The second method will be the incorporation of a modified waveform designed 
specifically to eliminate fouling caused by melatonin developed by Hensley et al. (2018). 
This waveform increases both the holding potential and scan rate of typical values in 
order to minimize the effects of fouling of the CFme. While these modifications have 
proven to reduce the fouling effects of melatonin, a drawback which has been observed 
is the decreased sensitivity to DA. Even with this knowledge, the melatonin-specific 
waveform should still prove useful for observing any trends in DA release. 
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The final method to be explored will be the use of amperometry. Under specific 
conditions amperometry has certain advantages and limitations. As opposed to applying 
a cyclic voltage potential, amperometry operates by maintaining a constant voltage 
potential. Previous work has shown that melatonin reacts with the electrode at +0.8V. 
Therefore, by maintaining a constant voltage of +0.6V we can observe the oxidation of 
DA and eliminate the possibility of fouling. It should be noted that the lack of cyclic 
voltage potentials offers no selectivity of analytes. To ensure we will be observing DA, 
release sites in the tissue will first be found using a traditional waveform known to be 
more sensitive and selective to DA (Patel, 2008).  
Tasimelteon 
 To provide additional support that the decrease in striatal DA release observed is 
a biological response to MT1 receptor activation, we utilized a melatonin receptor 
agonist. Tasimelteon has been used clinically since 2014 as an orally administered MT1 
and MT2 receptor agonist to treat sleep disorders. Though tasimelteon has a slightly 
reduced binding affinity to MT1 compared to melatonin, preliminary voltammetry work 
highlighted its experimental viability through relatively minor interaction with the 
electrode surface. Tasimelteon will be used to demonstrate that observed striatal DA 
release is not merely a product of electrode fouling and rather a function of MT1 
activation (Dhillon & Clarke, 2014). 
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Relevance and Purpose 
The primary purpose of this study is to elucidate the acute neurobiological 
effects of melatonin exposure on the release of DA within the caudate putamen of a 
mouse model. While previous studies have utilized protein assays to study melatonin 
exposure on cellular activity, we propose an ex vivo approach. By inserting the CFme 
directly into the caudate putamen of mouse brain slices for FSCV recording we will be 
able to progressively record DA release over a defined period of melatonin exposure. In 
order to elicit the strongest response, we hope to saturate MT1 and MT2 receptors by 
using multiple supraphysiological concentrations of melatonin in a range inspired by the 
work done by Paredes et al. (1999). 
 The evidence presented by the literature suggest that melatonin decreases 
striatal DA release from dopaminergic axon terminals which express the MT1 receptor. 
For a clinical application this could present an argument that the administration of 
melatonin to an individual with PD would be ineffective for treatment due to the 
already existing DA insufficiency which is rooted in the neuropathology of the disease. 
While we are not explicitly researching PD, the research conducted in this experiment 
could still add knowledge to the field of research exploring the therapeutic potential of 
melatonin on neurodegenerative diseases or neuropsychiatric disorders. 
Clinical studies on the application of melatonin for the treatment of 
neurodegenerative disorders has had mixed results. As described in Trotti & Karroum 
(2016), recent studies have shown that using melatonin to treat patients with 
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neurodegenerative diseases such as Parkinson’s fail to produce therapeutic results for 
treating motor PD (Pandi-Perumal et al., 2013; Willis & Armstrong, 1999) but show some 
antidepressant effects and sleep disorder improvement (Bassani et al., 2014). However, 
melatonin has shown to attenuate Dopaminergic neuronal cell death in a rotenone 
induced PD rat model (Carriere, Kang, & Niles, 2016) and a 6-hydroxyDA induced PD rat 
model (Yildirim et al., 2014). Promising results have also been observed in induced PD 
mouse models when supplemental melatonin was administered with L-DOPA (Naskar et 
al., 2013; Zaitone, Hammad, & Farag, 2013), likely attributed to melatonin’s natural role 
as an antioxidant for the reduction of oxidative stress seen by mitochondria in PD (Patki 
& Lau, 2011). 
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Chapter 3 
Materials and Methods 
Carbon Fiber Micro-Electrodes 
Carbon fiber micro-electrodes were fabricated using 7ɥm T-650 carbon fiber 
(Cytec Engineering) thread into a glass capillary tube (0.68mm ID/ 1.2mm OD) and 
pulled in a capillary puller (Sutter P77). Exposed carbon fiber was cut to a length of 50-
100ɥM and sealed in epoxy resin or paraffin wax then briefly washed with acetone or 
xylene, respectively.  
Animals 
Adult male C57BL/6J mice (Jackson Laboratories) were housed under a 12-hour 
day/night cycle with food and water available ad libitum. Mice selected for 
experimentation were anesthetized using isoflurane (1.5%, 2L/min O2) and then 
euthanized via cervical dislocation. The intact brain was removed from the skull via 
dissection and placed in ice-cold artificial cerebral spinal fluid (aCSF) buffer bubbled with 
carbogen (95%O2/5%CO2) and containing the following (in mM): 126 NaCl, 2.5 KCl, 1.2 
NaH2PO4, 2.4 CaCl2, 1.2 MgCl2, 25 NaHCO3, 11 glucose, and 0.4 l-ascorbic acid. A 
vibratome (Campden Instruments) filled with the same aCSF buffer was used to obtain 
300ɥm thick sagittal cross-sections of the brain. Slices were allowed to rest at room 
temperature while supplied with a constant flow of aCSF buffer until ready to use. All 
procedures were approved by and in compliance with the Grand Valley State University 
Institutional Animal Care and Use Committee.  
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Ex Vivo FSCV in Brain Slices 
Slices of mouse brain containing portions of the caudate putamen were placed in 
a 3D-printed flow chamber and held in place with a slice harp (Warner Instruments). 
aCSF buffer was continuously bubbled with carbogen and heated to 37°C before flowing 
through the chamber at a rate of approximately 1mL/min. Slices were given 1 hour to 
acclimate before FSCV work began, allowing for simultaneous preparation of the 
electrodes. Before tissue entry, electrodes were first submerged in the flowing aCSF and 
cycled for 15 minutes at 60Hz to clean the electrode surface, a protocol inspired by 
Takmakov et al. (2010). CFme were then lowered into the target tissue just until the 
entirety of the CFme was below the surface. DA release was electrically evoked via 
stimulation electrodes placed on the surface of the tissue slice on either side of the 
CFme entry site (figure 4). Recordings lasted 30 seconds with a stimulus onset delay of 5 
seconds, an intensity of 350uA, 1 pulse, 60Hz monophasic stimulation. Each trial 
consisted of 5 pre-drug recordings, 12 recordings during drug exposure, and 12 
recordings of post-drug washout. Melatonin concentrations of 10ɥM, 50ɥM, and 100ɥM 
were added to aCSF buffer and were exposed to the tissue during drug exposure 
periods. All recordings were given 5-minute refractory intervals to allow for the tissue to 
equilibrate. Experiments were also dedicated to observing the effects of 100ɥM 
tasimelteon exposure.  
An n=3 was collected for each melatonin concentration for each waveform. 
Pseudo-replication was avoided by ensuring that brain slices from a mouse were not 
exposed to the same concentration of melatonin twice. Parameters for FSCAV collection 
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maintain the same holding (-0.4V) and switching (+1.3V) potentials as traditional FSCV 
recording but increase the scan rate to 1200V/s with a frequency of 100Hz. For the 
melatonin specific waveform, a holding potential of +0.2V and a switching potential of 
+1.3V was utilized with a scan rate of 600V/s and frequency of 10Hz. Finally, 
amperometry was employed to hold a constant voltage potential of +0.6V at 60Hz to 
reduce melatonin fouling. When preparing to collect data with the melatonin-specific 
waveform and amperometry, DA release sites were first sought out using the traditional 
FSCV waveform (-0.4V-1.3V, 400V/s, 10Hz) due to high sensitivity to DA.  
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Figure 4. Experimental Setup – Electrode Placement: The left side of this figure is from 
a mouse brain atlas by Franklin & Paxinos (2008) used for reference when collecting 
brain slices. The right side of this figure is an image taken during experimentation, note 
the central location of the caudate putamen (CPu) on both sides of this figure. The 
CFme, located at the end of a pulled capillary (A) was positioned between two 
stimulating electrodes (B). The brain slice was immobilized with the aid of a metal slice 
harp with lycra strings (C). 
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Voltammetry in vitro 
Electrodes were saved after ex vivo work to be calibrated with 1uM DA to 
quantify electrode sensitivity. The electrodes were placed in a thin flow chamber 
submerged in calibration aCSF containing the following (in mM): 126 NaCl, 2.5KCl, 0.66 
NaH2PO4, 2 Na2HPO4, 2.4 CaCl2, 1.2 MgCl2, 11 glucose, and 0.4 l-ascorbic acid. The 
calibration aCSF pH was manually adjusted to 7.4 before it was used for electrode 
calibrations. Calibration recordings spanned a duration of 30 seconds, with calibration 
aCSF containing an additional 1ɥM DA timed to enter the flow chamber at 
approximately 10 seconds and be exposed to the electrode for roughly 10 seconds. 
Electrodes utilized the same waveforms used during experimental data collection. 
Calibrations were run until multiple consistent peak amplitudes for DA were produced.  
Additional FSCV work 
 Demonstration of melatonin interaction with the CFme utilizing the traditional 
FSCV waveform was carried out. An experimental environment was simulated by 
continuously exposing the CFme to an aCSF buffer containing 10ɥM melatonin with the 
addition and subsequent removal of 1ɥM DA in 5-minute intervals. A pipette-based 
calibration technique was utilized for DA introduction to the CFme, inspired by Ramsson 
(2016). 
Statistical analysis 
 The peak current produced by DA release (Dmax) was noted for each recording. 
To normalize data for statistical analysis, the 5 pre-drug recordings were averaged and 
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the remaining values for the drug exposure and washout periods were expressed as a 
ratio (%) of the pre-drug average. The relative ratios for each experimental group were 
then combined allowing for simplified analysis of statistical significance between data 
sets. Upon consultation with a statistician we decided on the utilization of generalized 
estimating equations (GEE) for the statistical analysis which was performed in SAS 
(version 9.4). For each of the two experimental recording periods, drug exposure and 
washout, the significance of change in Dmax was compared as a function of waveform, 
concentration, time, and combinations of these variables. 
Graphing 
 Raw data for background subtracted voltammograms, current verses time (IvT), 
and background current were output from files recorded in Demon Voltammetry 
Software (Wake Forest Innovations). All data was imported to and graphed utilizing 
Veusz graphing software.  
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Chapter 4 
Results & Discussion 
Summary of Results 
Figure 5 displays the average relative ratio of Dmax for each concentration of 
melatonin and respective waveforms used. Time -20 to 0 minutes represent the 5 pre-
exposure recordings before the introduction of melatonin to the brain slice. At time 0, 
brain slices were exposed to a 10ɥM, 50ɥM, or 100ɥM concentration of melatonin for 
60 minutes where 12 recordings were taken at 5-minute intervals. The final 12 time 
points, 65-120 minutes, span the drug washout period when melatonin has been 
removed from the incoming aCSF buffer. Dmax endpoints for the melatonin exposure 
and washout period have been compiled in Table 1 (Appendix A).  
 Upon initial assessment of the graphs, it is apparent that in most cases Dmax 
experiences a decrease upon melatonin exposure with varying responses to the 
washout period. We expected a dose-dependent response overall, but the data shows 
the melatonin-specific waveform and amperometry experienced a slightly greater mean 
decrease in Dmax with 50ɥM melatonin than 100ɥM. Additionally, change in Dmax 
across all waveforms appeared to have similar profiles under the influence of 50ɥM and 
100ɥM melatonin. The statistics support this initial observation.  
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Figure 5. Results Summary by Waveform: The mean Dmax for each melatonin 
concentration group has been plotted as a ratio of the 5 pre-exposure recordings (-20-0 
minutes). The melatonin exposure period occupies the time from 0 to 60 minutes, and 
the washout period occurs from 60 to 120 minutes. The beginning and end of melatonin 
exposure to the brain slice is marked with a dashed black line.  
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Statistical Results 
Tables 2 and 3 (Appendix A) outline the factors for which significant change in 
DA release is dependent upon using 100ɥM melatonin as a baseline. Upon observing DA 
release during melatonin exposure as a function of time and concentration across 
waveforms, GEE parameter estimates returned a p-value of 0.6835 for 50ɥM and a p-
value of 0.0081 for 10ɥM (Table 2). These results show that across waveforms, the 
trend of Dmax upon exposure to 100ɥM melatonin does not significantly differ from 
50ɥM but does significantly differ from 10ɥM. However, as displayed in Appendix A, 
Table 3 this trend does not continue into the washout period as 100ɥM does not differ 
from either 50ɥM (P=0.5371) nor 10ɥM (P=0.9765). 
Wald statistics for GEE analysis are outlined in Tables 4 and 5 (Appendix A). 
Significance of DA release as a function of time, concentration, and waveform had the 
greatest effect during the exposure period, seen by a P-value of 0.0043 (Appendix A, 
Table 4). This same effect, however, was not shared by the washout period as analysis 
yielded a P-value of 0.1304 (Appendix A, Table 5). These results indicate that overall 
observed change in Dmax over the course of the melatonin exposure period is heavily 
dependent on time, but during the washout period time does not hold the same effect. 
If the decrease in DA release observed was primarily attributed to fouling, then we 
would expect the signal to recover during the washout period as melatonin leaves the 
environment. This evidence supports the notion that the change in DA release observed 
is the result of a biological effect of melatonin on the dopaminergic axon terminals as 
opposed to fouling of the electrode. 
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Figures 6 and 7 represent the predicted linear model derived from GEE 
parameter estimates summarized in Tables 6 and 7, respectively (Appendix A). 
Observing the data as predicted linear models allows for a clearer and, more 
importantly, statistical lens through which we can observe results. Graphed in Figure 6, 
it is apparent that every concentration of each waveform during the melatonin exposure 
period exhibits some degree of negative slope over time indicating an overall decrease 
in Dmax. Considering the strong interaction that time has during this period as indicated 
by the Wald statistics, this representation is consistent with what we would expect 
while also displaying which group experienced the greatest decline in predicted Dmax.  
Observing the interaction of waveform and concentration on Dmax at each time 
point offers insight to how soon melatonin causes significant differences between test 
groups during the exposure period. Outlined in Table 8 (appendix A) are the Wald 
statistics for each time point. We can see that the P-values dip below 0.05 as soon as 25 
minutes into the exposure period and remain so for the duration of the hour with the 
one exception at 35 minutes. Based on this experiment, the data indicates that 
statistically significant change in Dmax upon melatonin introduction does not occur until 
at least 25 minutes into exposure. As previously described by the Wald statistics in 
Tables 4 and 5, the strong interaction of time does not carry into the washout period. 
  Figure 7 graphically represents the washout period which displays more gentle 
slopes than the exposure period while also exhibiting the lack of unidirectional slopes. 
This is the resulting behavior when significant change does not occur over the time 
course, reiterating the lack of strong interaction of time on change in Dmax. As 
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mentioned previously, lacking the significant interaction of time opposes the likelihood 
that fouling of the electrode surface is the primary contributor to the observed decrease 
in Dmax in the exposure period. All the waveforms utilized were chosen for their 
properties which reduce the fouling capacity of melatonin. With its constant holding 
potential, amperometry was expected to be the least susceptible to fouling by 
melatonin. Upon closer inspection of Figure 7, the three linear functions with the 
smallest slope all belong to the melatonin concentrations tested using amperometry. 
Disregarding time and observing Dmax as a function of concentration and waveform, 
statistical analysis finds that these linear functions are extremely similar to each other 
(Table 9, Appendix A). Considering the near-absent effect that melatonin washout has 
on amperometry, it becomes increasing likely that the decrease in Dmax observed using 
amperometry during the melatonin exposure period is indeed a result of biological 
function. As for the other waveforms, insight on the presence of fouling can be gained 
from analyzing the voltammetry data. 
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Figure 6. Predicted linear model of melatonin exposure period derived from GEE 
parameter estimates 
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Figure 7. Predicted linear model of melatonin washout period derived from GEE 
parameter estimates 
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Voltammetry Data 
Figures 8 and 9 display the voltammetry data recorded utilizing the FSCAV 
waveform for 10ɥM, 50ɥM, and 100ɥM melatonin concentrations respectively. While 
the changes in current amplitude of the cyclic voltammograms and IvT plots between 
experimental periods is the most immediately apparent feature, the data has already 
been summarized in Figure 5. What we are interested in are the properties that indicate 
impedance as explored by Meunier, Roberts, McCarty, & Sombers (2017). Their research 
shows that impedance will cause a decrease in sensitivity as well as a positive shift in 
voltage potential required for redox reactions of DA. Figure 11 illustrates voltammetry 
data from experiments utilizing the FSCAV waveform and melatonin specific waveform 
which exposed brain slices to the 100ɥM melatonin concentration. If either of these 
waveforms are susceptible to melatonin fouling, the evidence will present itself at our 
highest concentration. Positive shifts in the oxidation potential can be observed for both 
the FSCAV (Figure 11A) and melatonin specific (Figure 11B) waveforms with the 
background and background-subtracted plots experiencing a minor positive shift as well. 
While this evidence may initially seem contradictory, comparison to voltammetry data 
of CFme exposure to only 10ɥM melatonin utilizing the traditional FSCV waveform 
provides perspective on the oxidation shift which severe fouling can cause (Figure 12A). 
Although it is true that these two specialized waveforms still experienced a small degree 
of fouling, the relatively minor change in oxidation potential reveals that fouling likely 
had only a small effect on the decrease in Dmax observed. Though we are unable to 
quantify how much of the change in Dmax observed can be attributed to fouling due to 
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our methods of collection, minor observed impedance coupled with a lack of a time-
dependent change during the washout period indicates fouling present was minimal. 
The progression of change in aspects of voltammetry recordings over the course 
of the experiments have been outlined in Figures 8, 9, and 10. The background plot, 
cyclic voltammogram, and IvT plot for each concentration of melatonin has been 
selected from an experiment which best represents the mean Dmax of that respective 
group. The three data sets plotted on each graph represent the final recording of the 
pre-melatonin, melatonin exposure, and melatonin washout periods. Observing how 
these recordings change from exposure to washout periods provide insight to activity 
occurring at the electrode surface.  
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Figure 8. Data Collection Utilizing FSCAV Waveform: Background, background-
subtracted voltammogram, and current over time for 10ɥM (A), 50ɥM (B), and 100ɥM 
(C) melatonin exposure, respectively. For each graph the black line, red line, and blue 
line represent the final recording for the pre-melatonin, exposure, and washout 
experimental periods respectively.  
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Figure 9. Data Collection Utilizing Melatonin-specific Waveform: Background, 
background-subtracted voltammogram, and current over time for 10ɥM (A), 50ɥM (B), 
and 100ɥM (C) melatonin exposure, respectively. For each graph the black line, red line, 
and blue line represent the final recording for the pre-melatonin, exposure, and 
washout experimental periods respectively. 
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Figure 10. Data Collection Utilizing Amperometry: Current over time graphs for 10ɥM 
(A), 50ɥM (B), and 100ɥM (C) melatonin exposure. For each graph the black line, red 
line, and blue line represent the final recording for the pre-melatonin, exposure, and 
washout experimental periods respectively.  
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Figure 11. Progression of DA oxidation behavior during melatonin exposure utilizing 
tested waveforms: Background (left) and background-subtracted (right) cyclic 
voltammograms have been plotted to observe any susceptibility that the FSCAV (A) and 
melatonin specific (B) waveforms may have to melatonin fouling at 100ɥM. The dashed 
line represents the DA oxidation potential of the first recording (black). Subsequent 
recordings are colored to reflect the progression of time until concluding with red. 
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Figure 12. Comparative progression of DA oxidation behavior during melatonin 
exposure: Background (left) and background-subtracted (right) cyclic voltammograms 
have been plotted to observe susceptibility that the traditional FSCV waveform (A) has 
to melatonin fouling at 10ɥM in aCSF buffer. MT1 agonist tasimelteon (B) exposure to 
mouse brain tissue slice, read with FSCAV waveform. The dashed line represents the DA 
oxidation potential of the first recording (black). Subsequent recordings are colored to 
reflect the progression of time until concluding with red.  
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Activity on the Electrode Surface  
 As discussed previously, fouling of the electrode is a product of electroactive 
compounds becoming adsorbed to the surface resulting in decreased sensitivity. These 
compounds, including melatonin, persist on the surface for an extended period of time 
unless removed. As explored in Takmakov et al. (2010), CFmes can renew their surface 
given the right parameters. They found that application of a voltage greater than 1.0V 
will cause carbon on the surface of the electrode to degrade via oxidation of carbon into 
CO2, slowly renewing the surface. It was also discussed that the application of a more 
traditional waveform (-0.4V-1.3V, 400V/s) will almost completely restore the sensitivity 
of an electrode in 15 minutes when cycled at 60Hz. By calculating the total time this 
waveform spends renewing its surface in 15 minutes, we are able to create a benchmark 
for how long the FSCAV and melatonin specific waveform should take to renew their 
electrode surface.  
 
𝑇𝑜𝑡𝑎𝑙 𝑉𝑜𝑙𝑡𝑎𝑔𝑒 𝐴𝑏𝑜𝑣𝑒 1.0𝑉
𝑆𝑐𝑎𝑛 𝑅𝑎𝑡𝑒
× 𝑆𝑐𝑎𝑛 𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 × 60 𝑆𝑒𝑐𝑜𝑛𝑑𝑠 × 15 𝑀𝑖𝑛𝑢𝑡𝑒𝑠 
 Based on the work done by (Takmakov et al., 2010) and the above equation, we 
believe that 81 seconds spent above 1.0V is the standard for which to compare to our 
waveforms tested. Using the same equation to assess the experimental waveforms finds 
that in the same 15-minute period the FSCAV waveform spends 45 seconds cleaning its 
surface and the melatonin specific waveform only spends 9 seconds. This means that 
the time it takes for the FSCAV and melatonin specific waveforms to sufficiently renew 
their surfaces would require 27 minutes and 135 minutes, respectively. Given that we 
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allocated 60 minutes for the washout period in the absence of melatonin this reasoning 
gives evidence that any changes, or lack thereof, in Dmax observed with the FSCAV 
waveform after 27 minutes is likely a function of biological action. However, the same 
cannot be said for the melatonin specific waveform.  
 Using these required times for surface renewal brings additional context for the 
background data displayed in Figures 8 and 9. As we have concluded, both the FSCAV 
and Melatonin specific waveforms experience a degree of fouling contributing to the 
decrease and positive shift in background signal after 1 hour of melatonin exposure (red 
line). The capability of the electrode to renew its surface can be observed by the 
restoration of the background signal back to baseline 1 hour after removal of melatonin 
from the aCSF buffer (blue line). The restoration rate which we calculated is consistent 
with what is seen for the melatonin specific waveform, with the background returning 
to approximately half of what it was before melatonin exposure. This persistent 
depreciated background current indicates that the final recordings of Dmax taken with 
the melatonin specific waveform are likely not entirely accurate due to some fouling still 
present on the CFme.  
 This is not the case for the FSCAV waveform, where the background current 
experiences a full recovery or, in many cases, exceeds the baseline. To reiterate, it was 
calculated that the surface would renew itself in less than a half hour. Given the hour 
washout period, it is not surprising that the background current is restored. The 
implications of this is that the final recordings taken with the FSCAV waveform should 
be a reasonably accurate representation of the biological change in DA release.  As for 
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an explanation of the observed background exceeding baseline, it is likely a product of 
CFme etching also explored in depth by Takmakov et al. (2010). Background current is 
linearly proportional to scan rate and electrode surface area. As the CFme surface 
continues to renew itself, carbon is lost in the form of CO2 and the morphology of the 
surface transitions from smooth to rough. Since roughening of the surface increases the 
surface area, the increased background current follows suit. 
Outlier data 
 One data set which did not follow expected trends was the behavior of DA 
release observed during 10ɥM melatonin exposure when recording with the FSCAV 
waveform. Only one of our three slices tested experienced the expected pattern of 
decreased Dmax with minor restoration, while the other two actually experienced a 
moderate increase in Dmax upon melatonin exposure with little change into the 
washout period. Considering that this phenomenon occurred twice in the same test 
group, we believe there is more to the explanation besides possible error in procedure. 
Upon consultation of the literature, the contributor we believe to be at play is the 
diurnal expression of the MT1 receptor.  
 Much like the circadian role melatonin plays in the body, the MT1 receptor itself 
is under diurnal expression. Real-time PCR and western immunoblotting analysis have 
found low MT1 mRNA presence at night, but high MT1 receptor expression. Expression 
is inverse into daylight hours, with high MT1 mRNA and low MT1 receptor expression 
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(Uz et al., 2005). This information is important to discuss when retroactively considering 
the times of mouse sacrifice before experimentation.  
 As described in the methods, our mouse model was treated with a standard 12-
hour day-night cycle of light exposure beginning at 7am. Due to extensive time frame of 
experiments we often began preparation as early as 8am. However, equipment 
troubleshooting in the early stages could delay an animal sacrifice up to 3 hours into the 
light cycle. Therefore, it is possible that the lack of consistent decrease in Dmax among 
experimental groups exposed to 10ɥM melatonin could be attributed to the varied 
expression of the MT1 receptor. Additionally, similarity between and consistency within 
the experimental groups of 50ɥM and 100ɥM melatonin exposure suggest that 10ɥM 
melatonin may not be adequate to sufficiently saturate available MT1 receptors. While 
there are likely more complicated cellular mechanisms at play, sufficient receptor 
saturation and the role which circadian control has on MT1 receptor expression cannot 
be overlooked as possible contributors.  
Variability  
 Another occurrence with a dearth of explanation is the disparity between the 
washout periods of the FSCAV waveform and amperometry. There is great support in 
the literature that amperometry is not susceptible to fouling (Patel, 2008). Therefore, 
we believe that the change in Dmax observed by amperometry is likely the most 
accurate representation of the biological response to melatonin. However, what we 
have difficulty describing is why the endpoint mean Dmax for FSCAV at 50ɥM and 
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100ɥM remain ~20% compared to the persistence of ~75% which amperometry 
displays. Assuming our argument for surface renewal of the FSCAV electrode is correct, 
the last 30 minutes of FSCAV washout should also present data of the true biological 
response. While we should consider the variation of spatial CFme placement in relation 
to MT1 receptor localization, consistency among respective waveform sets in response 
to melatonin suggest that the most likely variable at play is the waveforms themselves. 
FSCAV and amperometry are functionally different in how they interact with DA at an 
electrochemical level. Considering the complex nature of surface interactions on the 
CFme, the possible explanation for this disparity could warrant an entire research 
project of its own. For this thesis we will conclude that, regardless of fouling, waveform 
selection could produce varied results if you are gathering longitudinal proportional 
data as performed in this project. 
Implications of results 
 A limitation of this study is simply the interpretation of a single product from 
what is a multivariate system of interaction. When considering the washout period 
there are actually two factors which can contribute to an observed restoration in Dmax. 
One is the removal of melatonin which would reduce impedance if the electrode is 
susceptible to fouling. However, the other should be a restoration in VGCC function as 
the inhibition of which is generally reversed over several seconds in normal synaptic 
regulation (Ford, 2014). If the extent of downstream effects by MT1 receptor activation 
only encompassed VGCC, then we would expect the 1 hour duration given during the 
washout period should be sufficient for a full recovery of Dmax. Since the Dmax remains 
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persistently impaired, even for amperometry recordings, then it is reasonable to suggest 
that the downstream effects of MT1 are possibly extending beyond just VGCC function. 
Perhaps the 1 hour of melatonin exposure is a sufficient time frame for MT1 activation 
to inhibit AC and reduce cAMP enough to downregulate downstream mechanisms 
relating to DA release. This hypothesis is supported by similar voltammetry results 
produced by tasimelteon exposure (Figure 12B).  
Summary  
 Our results found that despite variability between waveforms, all recording 
methods observed a decrease in Dmax in response to melatonin exposure. Analysis of 
all waveforms grouped together finds that time has a significant effect on change in 
Dmax upon melatonin exposure. Predicted linear modeling revealed significant change 
occurring as soon as 25 minutes into the exposure period. The melatonin washout 
period did not experience the same significant effect of time, supporting the hypothesis 
that fouling would not be a primary contributor to a change in Dmax.  
 Voltammetry data provided insight on our selected waveforms’ resistance to 
melatonin fouling. While the melatonin specific waveform has shown to be more 
resistant to fouling than FSCAV, the slow rate of surface renewal reduced the viability of 
end-point data. FSCAV, with a much faster surface renewal rate, still presented 
inconsistencies with amperometry. Amperometry, intended as a baseline for 
comparison due to its proven resistance to melatonin fouling, performed as expected 
with linear modeling suggesting the absence of fouling. While our initial goal was to 
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observe the acute effects of melatonin exposure on DA release, our results suggest that 
1 hour of MT1 receptor activation may be long enough to elicit significant 
downregulation of mechanisms involved with DA availability. 
Future Direction 
 Due to the complicated nature of voltammetry, studies which seek to investigate 
CFme surface interactions with analytes are valuable to the field. Our results suggest 
that observing proportional changes in Dmax could produce different results dependent 
on what waveform is utilized. Further exploration of this phenomenon through 
extensive buffer work would likely produce valuable knowledge for the field of 
voltammetry. Additionally, given the potential power this technique has on assessing 
the temporal response of cellular metabolism from receptor signaling, this experiment 
could benefit from extended amperometric study. Varying degrees of exposure and 
washout periods could give important insight to the time frame that metabolic action 
follows receptor signaling.  
 Validity of the results produced by this experiment could be tested by further 
study of the role which the presynaptic MT1 receptor plays on DA regulation. Based on 
our conclusions, performing a similar experiment on ex vivo tissue slices of MT1 
receptor knockout mice should not produce the same effects.  
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Appendix A 
Statistical Tables 
 
 
 
 
 
 
Table 1. Mean final Dmax for melatonin exposure and washout periods: summarized 
Mean and standard deviation for the final data collection of exposure (t=60) and 
washout (t=120) periods. 
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Table 2. GEE parameter estimates for melatonin exposure period 
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Table 3. GEE parameter estimates for melatonin washout period 
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Wald Statistics for Type 3 GEE Analysis 
Source DF Chi-Square Pr > ChiSq 
WF 2 10.69 0.0048 
time 1 229.46 <.0001 
Concentration 2 10.06 0.0065 
time*Concentration 2 26.60 <.0001 
time*WF 2 83.71 <.0001 
Concentration*WF 4 2.97 0.5629 
time*Concentration*WF 4 15.19 0.0043 
 
Table 4. Output of GEE analysis of melatonin exposure period: Significance of DA 
release ratios as a function of waveform (WF), time, and concentration of melatonin 
 
 
 
Wald Statistics for Type 3 GEE Analysis 
Source DF Chi-Square Pr > ChiSq 
WF 2 26.06 <.0001 
time 1 16.07 <.0001 
Concentration 2 20.40 <.0001 
time*Concentration 2 1.07 0.5865 
time*WF 2 12.64 0.0018 
Concentration*WF 4 15.62 0.0036 
time*Concentration*WF 4 7.11 0.1304 
 
Table 5. Output of GEE analysis of melatonin washout period: Significance of DA 
release ratios as a function of waveform (WF), time, and concentration of melatonin. 
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Table 6. Descriptive statistics of DA release by concentration and waveform (WF) 
during melatonin exposure period: Each subgroup value is derived from an N=3. Each N 
was normalized by dividing the value by average of the pre-melatonin recordings for 
that experiment.  
 
Table 7. Descriptive statistics of DA release by concentration and waveform (WF) 
during melatonin washout period: Each subgroup value is derived from an N=3. Each N 
was normalized by dividing the value by average of the pre-melatonin recordings for 
that experiment.  
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Table 8. Wald statistics for each time point during melatonin exposure period: Values 
given are in the order of Chi-square, degrees of freedom, and P-value.  
 
Table 9. Predicted mean and P-value for interaction of concentration and waveform 
over melatonin washout period. P-values which indicate significant difference between 
two data sets are denoted by (*). 
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